Journal
APOPTOSIS
Volume 21, Issue 4, Pages 473-488Publisher
SPRINGER
DOI: 10.1007/s10495-016-1214-9
Keywords
Autophagy; P-gp; NF-kappa B; Epirubicin; Chemotherapy resistance; Triple negative breast cancer
Categories
Funding
- National Science Foundation of China [81372575]
- Science and Technology Support Program of Gansu Province [1204FKCA172]
- Program for Changjiang Scholars and Innovative Research Team in University [IRT1137]
- Fundamental Research Funds for the Central Universities [lzu-jbky-2015-162]
- National Institute of Health [HL71895, HL085769]
Ask authors/readers for more resources
Epirubicin (EPI) is widely used for triple negative breast cancer (TNBC), but a substantial number of patients develop EPI resistance that is associated with poor outcome. The underlying mechanism for EPI resistance remains poorly understood. We have developed and characterized an EPI-resistant (EPI-R) cell line from parental MDA-MB-231 cells. These EPI-R cells reached stable growth in the medium containing 8 mu g/ml of EPI. They overexpressed P-glycoprotein (P-gp) and contained numerous autophagic vacuoles. The suppression of P-gp overexpression and/or autophagy restored the sensitivity of these EPI-R cells to EPI. We further show that autophagy conferred resistance to EPI on MDA cells by blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B)-mediated pro-apoptotic signals. Together, these results reveal a synergistic role of P-gp, autophagy, and NF-kappa B pathways in the development of EPI resistance in TNBC cells. They also suggest that blocking the P-gp overexpression and autophagy may be an effective means of reducing EPI resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available